JP6554095B2 - 結核組成物及びそれを使用する方法 - Google Patents

結核組成物及びそれを使用する方法 Download PDF

Info

Publication number
JP6554095B2
JP6554095B2 JP2016523852A JP2016523852A JP6554095B2 JP 6554095 B2 JP6554095 B2 JP 6554095B2 JP 2016523852 A JP2016523852 A JP 2016523852A JP 2016523852 A JP2016523852 A JP 2016523852A JP 6554095 B2 JP6554095 B2 JP 6554095B2
Authority
JP
Japan
Prior art keywords
mtb
antigen
antigens
composition
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016523852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529223A5 (enExample
JP2016529223A (ja
Inventor
ラヴィ・アナンザ
ナタリー・カディオー
トーマス・ジー・エヴァンズ
マイケル・ストーン
バリー・ウォーカー
Original Assignee
アエラス グローバル ティービー ワクチン ファウンデーション
アエラス グローバル ティービー ワクチン ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエラス グローバル ティービー ワクチン ファウンデーション, アエラス グローバル ティービー ワクチン ファウンデーション filed Critical アエラス グローバル ティービー ワクチン ファウンデーション
Publication of JP2016529223A publication Critical patent/JP2016529223A/ja
Publication of JP2016529223A5 publication Critical patent/JP2016529223A5/ja
Application granted granted Critical
Publication of JP6554095B2 publication Critical patent/JP6554095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016523852A 2013-06-25 2014-06-24 結核組成物及びそれを使用する方法 Active JP6554095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838872P 2013-06-25 2013-06-25
US61/838,872 2013-06-25
PCT/US2014/043889 WO2014210018A1 (en) 2013-06-25 2014-06-24 Tuberculosis compositions and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019124873A Division JP7269806B2 (ja) 2013-06-25 2019-07-04 結核組成物及びそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2016529223A JP2016529223A (ja) 2016-09-23
JP2016529223A5 JP2016529223A5 (enExample) 2017-08-03
JP6554095B2 true JP6554095B2 (ja) 2019-07-31

Family

ID=52111114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016523852A Active JP6554095B2 (ja) 2013-06-25 2014-06-24 結核組成物及びそれを使用する方法
JP2019124873A Active JP7269806B2 (ja) 2013-06-25 2019-07-04 結核組成物及びそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019124873A Active JP7269806B2 (ja) 2013-06-25 2019-07-04 結核組成物及びそれを使用する方法

Country Status (7)

Country Link
US (4) US10266574B2 (enExample)
EP (2) EP3013364B1 (enExample)
JP (2) JP6554095B2 (enExample)
CN (1) CN105431166B (enExample)
ES (1) ES2925950T3 (enExample)
WO (1) WO2014210018A1 (enExample)
ZA (1) ZA201509262B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
WO2017218867A1 (en) * 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
EP3474889A4 (en) * 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN108239660B (zh) * 2016-12-26 2021-08-10 上海生物制品研究所有限责任公司 一种重组结核病疫苗，其制备方法及应用
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
KR102135334B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물
CN116327906A (zh) * 2021-12-22 2023-06-27 中国人民解放军总医院第八医学中心 一种结核分枝杆菌串联dna疫苗w545及其制备方法与应用
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CN101198358B (zh) 2004-12-01 2013-06-26 Aeras全球Tb疫苗基金会 具有增强的逃出内体能力的重组bcg菌株
AU2006261445B2 (en) 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
US20090304750A1 (en) * 2005-12-15 2009-12-10 David Hone Novel prime-boost combinations of attenuated mycobacterium
MX2009010800A (es) * 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
CN101289496B (zh) 2008-05-30 2011-06-29 中国医学科学院医学生物学研究所 能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途
WO2010129339A2 (en) * 2009-04-28 2010-11-11 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
BR112012003380A2 (pt) * 2009-11-02 2016-11-16 Biocomo Co Ltd vacina contra tuberculose do tipo spray intranasal usando um vetor de paramyxovírus.
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
US20120003256A1 (en) 2010-03-01 2012-01-05 Huiling Han Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
CN104474538A (zh) 2014-08-13 2015-04-01 华中科技大学 一种重组卡介苗

Also Published As

Publication number Publication date
CN105431166B (zh) 2020-09-18
US20190322709A1 (en) 2019-10-24
JP2019187441A (ja) 2019-10-31
EP3013364A4 (en) 2017-05-31
EP4176897A1 (en) 2023-05-10
ES2925950T3 (es) 2022-10-20
US11014969B2 (en) 2021-05-25
EP3013364B1 (en) 2022-08-03
JP2016529223A (ja) 2016-09-23
US11787842B2 (en) 2023-10-17
US20240101612A1 (en) 2024-03-28
EP3013364A1 (en) 2016-05-04
CN105431166A (zh) 2016-03-23
US20210371474A1 (en) 2021-12-02
JP7269806B2 (ja) 2023-05-09
US20140377300A1 (en) 2014-12-25
US10266574B2 (en) 2019-04-23
ZA201509262B (en) 2017-11-29
WO2014210018A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US11787842B2 (en) Tuberculosis compositions and methods of using the same
US20230365631A1 (en) Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis
US12168047B2 (en) Tuberculosis antigen cassettes
EP2621540A2 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
AU2014232335B2 (en) Synthetic immunogens for prophylaxis or treatment of tuberculosis
JP2017511810A (ja) 免疫療法組成物、治療方法、及び診断方法
KR20200110678A (ko) 머켈 세포 폴리오마바이러스의 큰 및 작은 t 항원, 핵산 작제물 및 상기 항원으로부터 만들어진 백신, 및 상기 항원을 사용하는 방법
WO2021127580A1 (en) Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190705

R150 Certificate of patent or registration of utility model

Ref document number: 6554095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250